Browse our 650+ Publications
Latest Publications
Real world performance of the CALGB 10403 regimen in young adults in the United States
DaSilva B, et al.
Blood Neoplasia
May 2025
Authors and Affiliates
Brandon DaSilva1,2, Alicia Darwin1, Amy Zhang3, Rutu D. Vyas4, Kathryn Russell5, Jason S.
Gilbert6, Virginia Tan7, Susan Feldt8, Hannah Johnston9, Emily C Liang4,10, Adam S. DuVall9,
Michaela Liedtke11, Wendy Stock9, Ryan D. Cassaday4,5, Marc Schwartz12, Jessica T. Leonard13,
Lori S. Muffly14*, Marlise R. Luskin15
1Department of Medicine, Stanford University School of Medicine, Stanford, CA
2Division of Hematology Oncology, Department of Medicine, Columbia University, New York, NY
3Stanford University School of Medicine, Stanford, CA
4Clinical Research Division Fred Hutchinson Cancer Center, Seattle, WA
5University of Washington School of Medicine, Seattle, WA
6Department of Medicine, University of Colorado School of Medicine, Aurora, CO
7Department of Medicine, Oregon Health & Science University, Portland, OR
8Department of Medicine, University of Chicago, Chicago, IL
9Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
10Department of Medicine, University of Washington, Seattle, WA
11Stanford Cancer Center, Palo Alto, CA
12Division of Hematology, University of Colorado, Aurora, CO
13Department of Hematology & Medical Oncology, Oregon Health and Science University,
Portland, OR
14Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School
of Medicine, Stanford, CA
15Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
MA
Blood-based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Slade M, et al.
Clin Lymphoma Myeloma Leuk
May 2025
Authors and Affiliates
Michael J. Slade, MD, MSCI1*, Julie Fortier, PhD1, Abir Khaled, PhD2, Mark Fiala, PhD1, Zac McDonald,
PhD2, Mark A. Zaydman, MD, PhD3, Fei Wan, PhD4, Mark A. Schroeder, MD1, Keith Stockerl-Goldstein,
MD1, Liqiang Yang, PhD2, Ravi Vij, MD, MBA1
*Corresponding author
1Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA
2Rapid Novor, Kitchener, Ontario, Canada
3Division of Laboratory and Genomic Medicine, Department of Pathology, Washington University in Saint
Louis, St. Louis, MO, USA
4Division of Public Health Sciences, Washington University in Saint Louis, St. Louis, MO, USA
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang M, et al
J Clin Oncol
May 2025
Authors and Affiliates
Michael Wang, MD1; David Salek, MD2; David Belada, MD3; Yuqin Song, MD4; Wojciech
Jurczak, MD, PhD5†; Brad S. Kahl, MD6; Jonas Paludo, MD7; Michael P. Chu, MD8; Iryna
Kryachok, MD9; Laura Fogliatto, MD10; Chan Y. Cheah, DMSc11; Marta Morawska, MD,
PhD12,13; Juan-Manuel Sancho, MD14; Yufu Li, MD15; Caterina Patti, MD16; Cecily Forsyth,
MD17; Jingyang Zhang, PhD18; Robin Lesley, PhD18; Safaa Ramadan, MD, PhD19; Simon Rule,
MD, PhD19; Martin Dreyling, MD, PhD20 for the ECHO investigators*
1Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas,
Houston, TX, USA; 2Department of Internal Medicine, Hematology and Oncology, University
Hospital Brno, Brno, Czech Republic; 34th Department of Internal Medicine – Haematology,
Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic; 4Key
Laboratory of Carcinogenesis and Translational Research, Department of Lymphoma, Peking
University Cancer Hospital & Institute, Beijing, China; 5Pratia MCM Maków, Krakow, Poland;
6Washington University in St Louis, St Louis, Missouri, United States; 7Division of Hematology,
Department of Medicine, Mayo Clinic, Rochester, MN, USA; 8Department of Medical
Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada; 9Department of
Oncohematology, National Cancer Institute, Kyiv, Ukraine; 10Department of Clinical
Hematology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; 11Department of
Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia and Medical School,
University of Western Australia, Perth, Australia; 12Experimental Hematooncology Department,
Medical University of Lublin, Lublin, Poland; 13Hematology Department, St. John’s Cancer
Center, Lublin, Poland; 14Clinical Hematology Department, ICO-IJC-Hospital Germans Trias i
Pujol, Badalona, Spain; 15Department of Hematology, Henan Cancer Hospital, Zheng Zhou,
China; 16Oncohematology Unit, A.O.O.R. Villa Sofia Cervello, Palermo, Italy; 17Central Coast
Haematology, North Gosford, Australia; 18AstraZeneca, South San Francisco, CA, USA;
19AstraZeneca, Cambridge, UK; 20Medizinische Klinik III, Klinikum der Universitaet Munchen,
Muenchen, Germany
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
Aldoss I, et al.
Haematologica
May 2025
Authors and Affiliates
Ibrahim Aldoss,1 Jianying Zhang,2 Kathryn Shimamoto,3 Caner Saygin,3 Marjorie Robbins,4
Vaibhav Agrawal,1 Ahmed Aribi,1 Diren Arda Karaoglu,3 Hoda Pourhassan,1 Paul Koller,1 Haris Ali,1
Amanda Blackmon,1 Salman Otoukesh,1 Karamjeet Sandhu,1 Brian Ball,1 Andrew S. Artz,1 Monzr
M. Al Malki,1 Amandeep Salhotra,1 Jose Tinajero,5 Zhaohui Gu,6,7 Ian Lagman,1 Michelle
Velasquez,1 Jacqueline Dang,1 Pamela S. Becker,1,8 Michelle Afkhami,9 Lucy Ghoda,6,8,10 Wendy
Stock,3 Stephen J. Forman,1 Anthony Stein,1 Guido Marcucci1,6,8 and Vinod Pullarkat1
1Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;
2Department of Biostatistics, City of Hope, Duarte, CA; 3Department of Medicine-Hematology
and Oncology, University of Chicago, Chicago, IL; 4Clinical Translational Project Development,
City of Hope, Duarte, CA; 5Department of Pharmacy, City of Hope, Duarte, CA; 6Beckman
Research Institute, City of Hope, Duarte, CA; 7Computational and Quantitative Medicine, City
of Hope, Duarte, CA; 8Hematological Malignancies Translational Science, City of Hope,
Duarte, CA; 9Department of Pathology, City of Hope, Duarte, CA and 10Department of
Research Business Operations, City of Hope, Duarte, CA, USA
A phase 2, randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma
Holstein S, et al.
Blood
April 2025
Authors and Affiliates
Sarah A. Holstein,1 Shebli Atrash,2 Hira Mian,3 Meletios A. Dimopoulos,4
Fredrik Schjesvold,5 Rakesh Popat,6 Nishi Shah,7 Moshe E. Gatt,8 Christian B. Gocke,9
Laurent Frenzel,10 Cyrille Touzeau,11 Meral Beksac,12 Salomon Manier,13 Hila Magen,14
Patrick Travis,15 Omar Nadeem,16 Kaveri Suryanarayan,17 Cheryl Li,17 Shuli Li, 17 Allison
Nelson,17 Dasha Cherepanov,17 Xavier Parot,17 and Dan T. Vogl18
Affiliations:
1. University of Nebraska Medical Center, Omaha, NE, USA
2. Levine Cancer Institute, Charlotte, NC, USA
3. McMaster University, Hamilton, Canada
4. Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian
University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul,
South Korea
Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece
5. Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo,
Norway
6. University College London Hospital, London, UK
7. Montefiore Medical Center, New York, NY, USA
8. Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem,
Jerusalem, Israel
9. Johns Hopkins University, Baltimore, MD, USA
10. Necker Hospital, Paris, France
11. Centre Hospitalier Universitaire de Nantes, Nantes, France
12. Istinye University Ankara Liv Hospital, Ankara, Turkey
13. Lille University Hospital, Lille, France
14. Department of Hematology Chaim Sheba Medical Center, Ramat-Gan, Faculty of
Medicine, Tel Aviv University, Tel-Aviv, Israel
15. Highlands Oncology Group, Springdale, AR, USA
16. Dana-Farber Cancer Institute, Boston, MA, USA
17. Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA
18. Abramson Cancer Center, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA, USA
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy
Bal S, et al.
Blood Cancer Journal
April 2025
Authors and Affiliates
Susan Bal 1,2,8, Tylan Magnusson1,8, Gayathri Ravi1,2, Smith Giri1,2, Kelly Godby1,2, Binod Dhakal 3, Natalie S. Callander 4,Rebecca W. Silbermann5, Bhagirathbhai Dholaria 6, Vishnu B. Reddy7 and Luciano J. Costa 1,2
1Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. 2
O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham,
Birmingham, AL, USA. 3
Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 4
Division of Hematology, Department of
Medicine, Medical Oncology and Palliative Care, Wisconsin Institutes for Medical Research, Madison, WI, USA. 5
Division of Hematology/Medical Oncology, Knight Cancer Institute,
Oregon Health & Science University, Portland, OR, USA. 6
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. 7
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA. 8
These authors contributed equally: Susan Bal, Tylan Magnusson.
Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Gregory W, et al.
Clinical Cancer Research
April 2025
Authors and Affiliates
Walter M. Gregory1, Thomas J. Prior2, J. Blake Bartlett3, Pieter Sonneveld4, Meletios A. Dimopoulos5,
Philippe Moreau6, Saad Usmani7, and Thierry Facon8
1Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.
2Janssen Research & Development, Spring House, Pennsylvania. 3Janssen Research
& Development, LLC, Raritan, New Jersey. 4Erasmus MC Cancer Institute,
Rotterdam, the Netherlands. 5Department of Clinical Therapeutics, School of
Medicine, National and Kapodistrian University of Athens, Alexandra General
Hospital, Athens, Greece. 6Hematology Department, University Hospital Hˆotel-
Dieu, Nantes, France. 7Memorial Sloan Kettering Cancer Center, New York, New
York. 8University of Lille, CHU Lille, Lille, France.
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP
Nijland M, et al.
Blood Advances
April 2025
Authors and Affiliates
Marcel Nijland 1, Djamila E Issa 2, Johanna A A Bult 1, Dries Deeren 3, Gerjo A Velders 4, Marten R Nijziel 5, Yorick Sandberg 6, Vibeke Kj Vergote 7, Margriet Oosterveld 8, Rob Fijnheer 9, Rolf Brouwer 10, Rinske Boersma 11, Kalung Wu 12, Laurens Nieuwenhuizen 13, Joost Sp Vermaat 14, Roel J W van Kampen 15, Wim E Terpstra 16, Sylvia Snauwaert 17, Marjolein Wm van der Poel 18, Eva de Jongh 19, Marc Durian 20, Leonie Strobbe 21, Aart Beeker 22, Alain Pa Gadisseur 23, Roos Van Rijn 24, Otto J Visser 25, Jeanette Doorduijn 26, Tjeerd J F Snijders 27, Matthijs H Silbermann 28, Daphne de Jong 29, Martine E D Chamuleau 30, Rogier Mous 31, Mathilde Jalving 1, Heleen Visser-Wisselaar 32, Sonja Jansen van den Bergh 32, Gerben Jc Zwezerijnen 33, Edwin Bremer 1, Mirian Brink 34, Arjan Diepstra 1, Dana A Chitu 35, Harry R Koene 36, Josée M Zijlstra 37
1University Medical Center Groningen, Groningen, Netherlands.
2Jeroen Bosch hospital, Den Bosch, Netherlands.
3AZ Delta, Roeselare, Belgium.
4Hospital Gelderse Vallei, Ede, Netherlands.
5Catharina Cancer Institute, Eindhoven, Netherlands.
6Maasstad Hospital, Rotterdam, Netherlands.
7UZLeuven, Leuven, Belgium.
8Canisius-Wilhelmina Hospital, Nijmegen, Netherlands.
9Meander Medical Centre, Amersfoort, Netherlands.
10Reinier de Graaf Hospital, Delft, Netherlands.
11Amphia Hospital, Breda, Netherlands.
12ZNA Stuivenberg, Antwerp, Belgium.
13Maxima Medical Center, Veldhoven, Netherlands.
14Leiden University Medical Center, Leiden, Netherlands.
15Zuyerland Medical Center, Sittard-Geleen, Netherlands.
16Olvg, Amsterdam, Netherlands.
17AZ Sint-Jan Hospital Bruges, Bruges, Belgium.
18Maastricht University Medical Center, Maastricht, Netherlands.
19Albert Schweitzer Hospital, Dordrecht, Netherlands.
20ETZ Tilburg, Tilburg, Netherlands.
21Gelre ziekenhuizen, Zutphen, Netherlands.
22Spaarne Gasthuis, Hoofddorp, Netherlands.
23Antwerp University Hospital, Edegem, Belgium.
24Leeuwarden, Netherlands.
25Isala Clinic, Zwolle, Netherlands.
26Erasmus MC, Cancer Institute, Rotterdam, Netherlands.
27Medical Spectrum Twente (MST), Enschede, Netherlands.
28Tergooi Hospital, Hilversum, Netherlands.
29Netherlands Cancer Institute, Amsterdam, Netherlands.
30Amsterdam UMC, Vrije Universtiteit, Cancer Center Amsterdam, Amsterdam, Netherlands.
31University Medical Center Utrecht, Utrecht, Netherlands.
32Erasmus MC Cancer Institute, Rotterdam, Netherlands.
33Amsterdam UMC, location VUMC, Cancer Center Amsterdam, Amsterdam, Netherlands.
34Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands.
35Erasmus MC Rotterdam, The Netherlands, Rotterdam, Netherlands.
36St. Antonius Ziekenhuis, Nieuwegein, Netherlands.
37Amsterdam UMC, Amsterdam, Netherlands.
Daratumumab for newly diagnosed multiple myeloma: pooled analysis of patients aged >/65 years from GRIFFIN and PERSEUS
Rodriguez-Otero P, et al.
Clinical Lymphoma Myeloma & Leukemia
April 2025
Authors and Affiliates
Paula Rodriguez-Otero,a Peter M. Voorhees,b Mario Boccadoro,c Jacob Laubach,d Hermann
Einsele,e Douglas W. Sborov,f Meletios A. Dimopoulos,g Annemiek Broijl,h Roberto Mina,i
Andrew Spencer,j Fredrik Schjesvold,k Rebecca Silbermann,l Francesca Gay,i Luciano J. Costa,m
Aurore Perrot,n Yanfang Liu,o Jianping Wang,p Anna Sitthi-Amorn,p Robin Carson,p Annelore
Cortoos,q Saad Z. Usmani,r Paul G. Richardson,d Philippe Moreau,s Pieter Sonneveld,h and
Jonathan L. Kaufmant
aDepartment of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Navarra,
Spain; bLevine Cancer Institute, Atrium Health Wake Forest University School of Medicine,
Charlotte, NC, United States; cMyeloma Unit, Division of Hematology, University of Torino,
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy;
dDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States; eUniversity
Hospital Würzburg, Department of Internal Medicine II, Würzburg, Germany; fHuntsman
Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, United States;
gNational and Kapodistrian University of Athens, Athens, Greece; hDepartment of Hematology,
EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands; iDivision of Hematology 1,
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, and Department
3
of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; jMalignant
Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University,
Melbourne, Australia; kOslo Myeloma Center, Department of Hematology, Oslo University
Hospital, Oslo, Norway, and KG Jebsen Center for B-cell Malignancies, University of Oslo,
Oslo, Norway; lKnight Cancer Institute, Oregon Health & Science University, Portland, OR,
United States; mUniversity of Alabama at Birmingham, Birmingham, AL, United States; nCHU
de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France;
oJohnson & Johnson, Beijing, China; pJohnson & Johnson, Spring House, PA, United States;
qJohnson & Johnson, Horsham, PA, United States; rMemorial Sloan Kettering Cancer Center,
New York, NY, United States; sHematology Department, University Hospital Hôtel-Dieu,
Nantes, France; tWinship Cancer Institute, Emory University, Atlanta, GA, United States.